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ABSTRACT 
Background: Acute heart failure (AHF) is a heterogeneous disorder with most of the patients 
presenting with breathlessness along with varying degrees of peripheral edema. The presence of 
peripheral edema suggests that volume overload is the cause of decompensation leading to AHF, 
while breathlessness in the absence of edema may reflect a “vascular phenotype”. This analysis 
investigated the characteristics, therapeutic response and outcome of patients with AHF, with 
and without overt peripheral edema in the RELAX-AHF trial. 
Methods:  Physician-assessed edema scores at baseline were used to categorize the population 
into those with no /mild edema (score 0 or 1+) and moderate/severe edema (score 2+ or 3+). The 
effect of serelaxin versus placebo was assessed within each subgroup. 
Results: Patients with moderate/severe edema (n = 583; 50.5%) were more likely to have severe 
dyspnea, orthopnea (>30 degrees), rales (≥1/3) and elevated jugular venous pressure (>6 cm) 
than the patients with little or no peripheral edema (n=571; 49.5%) The relative benefits of 
serelaxin in terms of reduction in breathlessness, lower diuretic requirements, decreased length 
of initial hospital stay and days in ICU/CCU, and improved prognosis (180-day cardiovascular 
and all-cause mortality) were generally similar for patients with or without peripheral edema. 
However, as patients with moderate/severe peripheral edema had worse outcomes, the absolute 
benefit was generally greater than in patients with no/mild edema.    
Conclusions: Overall, patients with AHF and moderate/severe peripheral edema have a worse 
prognosis but appear to receive similar relative benefit and perhaps greater absolute benefit from 
serelaxin administration.  
Keywords: no/mild edema, moderate/severe edema, acute heart failure, serelaxin 
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INTRODUCTION 
With a few recent exceptions, the outcomes of randomized clinical trials in acute heart 
failure (AHF) have been disappointing(1-5). Methodological aspects of clinical trials in terms of 
study design, endpoint- and patient-selection, as well as intrinsic properties of the experimental 
interventions could account for some of these unsatisfactory findings(6). As AHF is 
heterogeneous in its etiology, pathophysiology, and clinical presentation, it should perhaps not 
be treated as a single clinical entity. It is plausible that while some treatments may have better 
efficacy in certain patient populations, they may not be as effective in others and therefore, on 
average, fail. Hence, a better segmentation of the AHF patient population, and development of 
therapies that target specific pathophysiological mechanisms, might yield greater success than 
would a ‘one-size-fits all’ model.  
The clinical presentation of AHF can be diverse (7). While dyspnea is typically the most 
common cause for patients seeking consultation, many patients with AHF also present with 
varying degrees of peripheral edema (8,9). The underlying pathophysiology and therapeutic 
needs for patients presenting with progressive increase in exertional dyspnea and severe 
peripheral edema may be different from those who present with a sudden onset of severe 
dyspnea at rest with little or no peripheral edema. Patients in the latter group develop symptoms 
and signs of pulmonary congestion without overt evidence of fluid retention. This suggests fluid 
redistribution into the lungs as the underlying pathophysiological mechanism requiring 
immediate medical intervention with vasodilator rather than diuretic agents (9-11). A minority of 
patients with AHF are also admitted with clear signs and symptoms of hypo-perfusion and low 
cardiac output (cardiogenic shock), representing a subgroup of patients with AHF with an 
ominous prognosis (7,8). 
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Serelaxin is a recombinant protein identical in structure to the naturally occurring human 
pregnancy hormone, relaxin-2 (1,2). Previous trials have shown that serelaxin improves dyspnea, 
signs of congestion and, subsequently, reduces cardiovascular (CV) and all-cause mortality for 
up to 6 months after completion of 48-hour intravenous (IV) infusion(1,2). Whether there are 
differences in baseline characteristics and outcomes in patients with peripheral edema versus 
those without is unknown. We therefore investigated the characteristics, therapeutic response, 
and outcome of patients enrolled in the RELAX-AHF trial who at baseline either had substantial 
peripheral edema, indicating progressive fluid accumulation, or mild/no peripheral edema, 
suggesting fluid redistribution as the dominant underlying pathophysiology (9).  
 
 METHODS  
This is a post-hoc analysis of the RELAX-AHF trial (clinicaltrial.gov identifier: 
NCT00520806). RELAX-AHF was an international, multicenter study that compared the 
efficacy of serelaxin versus placebo, in addition to standard of care, in patients admitted with 
AHF. The trial design and results have been reported previously (1,12). Patients were 
randomized within 16 hours of hospital presentation to either receive IV serelaxin or matching 
placebo for 48 hours, in addition to the standard of care for AHF. Pre-specified eligibility criteria 
included breathlessness at rest or from minimal exertion, elevated plasma concentrations of 
natriuretic peptides (brain natriuretic peptide [BNP] ≥350 pg/mL or N-terminal fragment of pro-
BNP [NT-pro-BNP] ≥1400 pg/mL), a chest X-ray with  an evidence of pulmonary congestion, 
mild to moderate renal insufficiency (estimated glomerular filtration rate [eGFR] ≥30 to ≤ 75 
ml/min/1.73m2), SBP>125 mmHg, and should have received at least 40 mg of IV furosemide (or 
equivalent) therapy prior to screening (1,13). The key outcome measures for this analysis are 
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described in the statistical analysis section. The in-hospital phase focused on symptoms and signs 
at different time points, diuretic requirements, blood pressure (BP) and length of stay (LOS). 
Worsening heart failure (WHF) was assessed through Day 5 and morbidity and mortality were 
assessed up to 6 months. 
Data Collection  
During the RELAX-AHF trial, investigators assessed the signs and symptoms of AHF 
including dyspnea on exertion (New York Heart Association [NYHA] class), orthopnea, rales, 
jugular venous pressure (JVP), and the presence of peripheral edema at scheduled time points 
through Day 14. These physician assessments of signs and symptoms were scored as follows: 
dyspnea on exertion (none, mild or moderate) or at rest (severe) corresponding to NYHA class I-
IV, clinical evidence of pulmonary congestion assessed by auscultation (no rales, rales <1/3, 1/3–
2/3, or >2/3), orthopnea (none, 1 pillow, 2 pillows, or >30 degrees), and JVP (<6 cm, 6-10 cm, 
>10 cm or not evaluable). Peripheral edema was assessed on a 0–4 scale, with scores of 0 to 1+ 
classified as no or mild edema and 2+ and 3+ as moderate to severe edema. Only baseline edema 
was used to define the subgroups. Body mass index (BMI) was based on actual weight 
uncorrected for the severity of edema 
Statistical Analysis  
Baseline characteristics (including demographic, clinical and HF characteristics) were 
summarized using descriptive statistics (i.e. n, mean, standard deviation [SD], 95% confidence 
interval [CI], median, interquartile range [IQR], minimum, and maximum).  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Page 9 of 36 
 
For continuous variables, subgroups were compared using two-sample t-tests or 
Wilcoxon rank sum test as appropriate, and categorical variables were compared using chi-
square (χ2) tests. 
For each efficacy endpoint, within each of the subgroups, treatment effects were assessed 
using an analysis of covariance (ANCOVA) model for continuous outcomes and the least square 
mean (LSM) difference was reported accordingly. Logistic regression was used to assess the 
treatment effects for binary outcomes and the odds ratios (OR) was provided. For time-to-event 
outcomes, treatment effects were assessed by Cox proportional hazard regression analysis and 
the hazard ratios (HR) were reported. 
The 95% CIs for each of the above estimated treatment effect along with the p-value for 
between-treatment comparisons were reported based on the aforementioned statistical models 
including treatment (serelaxin vs. placebo) as a major factor. Additionally, for each of the time-
to-event outcomes, p-values for treatment effects based on the log-rank test were also reported 
within each subgroup. Possible subgroup-by-treatment interactions were assessed from a 
separate model including the two subgroups, treatment arms, and the subgroup-by-treatment 
interaction in the model.  The p-value based on the type-3 χ2 test for the subgroup-by-treatment 
interaction term was reported accordingly. Because the endpoints, ‘length of initial hospital 
stay’, ‘days in intensive care unit/cardiac care unit (ICU/CCU)’, and ‘days alive out of hospital 
through Day 60’ do not follow the normality assumption for parametric tests, the treatment effect 
was expressed as median difference and 95% CI  based on Hodges-Lehmann estimation in 
addition to the LSM and 95% CI . The p-values were based on non-parametric Wilcoxon rank 
sum test. 
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Kaplan-Meier plots for the estimated cumulative event rate over time were provided for 
the two treatment arms within each of the two subgroups (a total of 4 curves) for the following 
time-to-event outcomes: all-cause and CV mortality through Day 180, and WHF through Day 5. 
For all analyses, two-sided p values with an alpha level of 0.05 were considered as 
statistically significant. All analyses were conducted on an intent-to-treat basis. Statistical 
Analysis software (SAS) release 9.4 (SAS Institute, Cary, NC, USA) was used for all analyses. 
The RELAX-AHF study and this analysis were sponsored by Novartis Pharma AG. The authors 
are solely responsible for the design and conduct of this study, all study analyses, drafting and 
final contents of this manuscript. The editorial and formatting support for the manuscript was 
provided by a scientific writer. 
  
 
RESULTS 
Of the 1161 patients randomized in the RELAX-AHF trial, 1154 reported the presence or 
absence of peripheral edema at baseline. Of these, 583 (50.5%) had little or no edema (no/mild 
edema subgroup) and 571 (49.5%) had overt peripheral edema (moderate/severe edema 
subgroup). 
Patients in the no/mild edema subgroup were slightly older, had a lower BMI, and were 
more often women, compared with those in the moderate/severe edemas subgroup (Table 1). 
Clinical signs, including BP, heart and respiratory rates and patient-reported severity of dyspnea 
at baseline (assessed by the visual analog scale [VAS] score) were similar in both the subgroups. 
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Time from presentation to randomization was shorter for the moderate/severe edema subgroup 
(7.3 hours) compared with the no/mild edema subgroup (8.5 hours; p<0.0001) (Table 1).  
Physician assessment of signs and symptoms of HF at baseline indicated that a higher 
proportion of patients in the moderate/severe edema subgroup, compared with the no/mild edema 
subgroup had severe dyspnea (71.1% vs. 60.5%, respectively; p=0.0002), severe orthopnea (>30 
degrees, 45.1% vs. 34.0 %; p< 0.0001) and overt signs of pulmonary congestion as demonstrated 
by the presence of rales ≥1/3 (60.6 % vs. 48.2 %; p <0.001). The proportion of patients with an 
elevated JVP (≥6 cm) was also higher in the moderate/severe edema subgroup than the no/mild 
edema subgroup (p <0.0001) (Table 1).  
Table 1: Comparison of baseline characteristics between patients with no/mild edema (baseline 
edema score= 0/1) subgroup vs moderate/severe edema subgroup (baseline edema score = 2/3)   
 
Baseline Characteristics 
No/mild 
(Total N=583) 
Moderate/severe 
(Total N=571) 
p-value
†
 
Demographics 
Age, years 72.9 (11.4) 71.2 (11.0) 0.0090* 
Male: n (%) 345 (59.2) 374 (65.5) 0.0267* 
White: n (%) 553 (94.8) 540 (94.6) 0.8297 
Clinical characteristics    
BMI, kg/m
2
 27.8 (5.2) 30.8 (5.8) <.0001* 
Systolic blood pressure, mmHg 142.0 (16.6) 142.4 (16.5) 0.6586 
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Diastolic blood pressure, mmHg 79.0 (14.2) 79.1 (14.3) 0.8987 
Heart rate, bpm 80.5 (15.0) 78.9 (14.9) 0.0729 
Respiratory rate, breaths per minute 21.6 (4.6) 22.2 (4.6) 0.0578 
Physician assessment of signs and symptoms of HF 
Dyspnea on exertion
‡
, n/N (%) 
Proportion of patients with severe dyspnea, 
including at rest 
 
348/575 (60.5) 
 
401/564 (71.1) 
 
0.0002* 
Orthopnea
§
, n/N (%) 
Proportion of patients with orthopnea >30 
degrees 
198/583 (34.0) 257/570 (45.1) 0.0001* 
Edema, n/N (%) 
Proportion of patients with edema score >1 
339/583 (58.1) 571/571 (100.0) < .0001* 
Rales
║
, n/N (%) 
Proportion of patients with rales≥ 1/3 
281/583 (48.2) 346/571 (60.6) < 0.0001* 
JVP
¶
, n/N (%) 
Proportion of patients with JVP≥ 6 cm 
371/569 (65.2) 478/556 (86.0) < .0001* 
Dyspnea by VAS scale 45.0 (19.7) 43.3 (20.2) 0.1445 
Heart failure characteristics 
LVEF (%) 38.6 (14.2) 38.5 (14.9) 0.9018 
Ischemic heart disease, n/N (%) 304/583 (52.1) 291/571 (52.0) 0.9647 
Subjects with history of congestive heart failure, 
n/N (%) 
404/583 (69.3) 452/571 (79.2) 0.0001* 
NYHA class 30 days prior, among those with history of congestive HF
#
, n/N (%) 
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Intention-to-treat set with non-missing baseline edema score, data are presented as mean (SD) unless otherwise 
specified, *significant difference between “no/mild edema” vs. “moderate/severe edema”, p < 0.05 
†
p-values were based on two-sample t-test for continuous variables and chi-square test for categorical variables; 
‡
Severity of dyspnea on exertion was assessed as none (score=0),  mild (score=1), moderate (score=2), severe 
including dyspnea at rest (score=3); 
§
severity of orthopnea assessed as none (score=0), 1 pillow, 10 cm (score=1), 2 
pillows, 20 cm (score=2), >30 degrees (score=3); 
║
Rales assessed as no rales (score=0), rales <1/3 (score=1), rales 
1/3-2/3 (score=2), rales >2/3 (score=3); 
¶
JVP assessed as <6 cm (score=0), 6-10 cm (score=1), >10 cm (score=2); 
I 15/399 (3.8) 8/447 (1.8) 0.2290 
II 142/399 (35.6) 159/447 (35.6)  
III 174/399 (43.6) 213/447 (47.6)  
IV 68/399 (17.0) 67/447 (15.0)  
Time from presentation to randomization, hours 8.5 (4.6) 7.3 (4.6) <0.0001* 
HF hospitalization in past year, n/N (%) 175/583 (30.0) 220/571 (38.5) 0.0023* 
Number of HF hospitalizations in past year 1.5 (1.4) 1.7 (1.3) 0.2490 
Comorbidities, n (%)    
Hypertension 495 (84.9) 504 (88.3) 0.0942 
Diabetes mellitus 235 (40.3) 313 (54.8) < .0001* 
Stroke or other cerebrovascular event 80 (13.7) 76 (13.3) 0.8378 
Asthma, bronchitis, or COPD 85 (14.6) 96 (16.8) 0.2970 
Atrial fibrillation at screening 215 (36.9) 261 (45.7) 0.0023* 
History of atrial fibrillation or flutter 281 (48.2) 318 (55.7) 0.0109* 
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#
There were 2 subjects in the “no/mild edema” and 8 subjects in the “moderate/severe edema” subgroup with history 
of congestive heart failure but without NYHA classification 
BMI, body mass index; bpm, beats per minute; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood 
pressure; HF, heart failure; JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; NYHA, New 
York Heart Association;  HF, heart failure; JVP, jugular venous pressure;  DOE, dyspnea on exertion; VAS, visual 
analogue scale; COPD, chronic obstructive pulmonary disease  
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There were no baseline differences between the two subgroups with regards to history of 
hypertension and ischemic heart disease, NYHA class prior to admission or left ventricular 
ejection fraction (LVEF) (Table 1). However, patients in the moderate/severe edema subgroup 
were more likely to have a prior history of congestive HF, were more likely to have been 
hospitalized for HF in the past year, had a higher prevalence of atrial arrhythmias and diabetes 
mellitus and were more likely to have an implantable cardiac defibrillator (ICD) with or without 
biventricular pacing (p<0.05 for all). Each subgroup received similar background treatment for 
HF at baseline (Table 2). Patients in the moderate/severe edema subgroup had higher plasma 
concentrations of creatinine (p=0.032), uric acid (p=0.0018), blood urea nitrogen (BUN) 
(p=0.0002) and Cystatin C (p<0.0001) than patients in the no/mild edema subgroup, while the 
eGFR was similar in both subgroups (p=0.27). Plasma BNP and NT-proBNP levels and the 
proportion of patients with an elevated troponin T levels at baseline were also similar between 
subgroups (Table 2). Analysis of NT-proBNP levels in patients with or without atrial fibrillation 
(AF) at baseline indicated that in patients without AF, plasma NT-proBNP was higher in the 
no/mild edema subgroup compared with the moderate/severe edema subgroup (median [IQR]: 
5110 [2732.0, 9904.5] ng/L vs. 4124 [2379.0, 8147.0] ng/L; p = 0.0257). In contrast, no 
significant differences in NT-proBNP levels were observed between the two subgroups in 
patients with AF. (Table 2) 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Page 16 of 36 
 
Table 2: Comparison of therapies and key laboratory variables at baseline between patients with 
“no/mild edema” and “moderate/severe edema” subgroups  
 
Baseline Characteristics 
No/mild 
(Total N=583) 
Moderate/severe 
(Total N=571) 
p-value
†
 
Devices, n (%)    
   Pacemaker 63 (10.8) 58 (10.2) 0.7192 
   Implantable cardiac defibrillator (ICD) 66 (11.3) 88 (15.4) 0.0410* 
   Biventricular pacing 42 (7.2) 71(12.4) 0.0028* 
Medication (Day 0, except nitrates), n (%)    
   ACE inhibitor 330 (56.6) 301 (52.7) 0.1845 
   Angiotensin-receptor blocker 83 (14.2) 102 (17.9) 0.0932 
   Beta-blocker 402 (68.9) 389 (68.1) 0.7621 
   Aldosterone antagonist 174 (29.8) 191(33.4) 0.1880 
   IV loop diuretics 583 (100.0) 571 (100.0) ----- 
   Digoxin 112 (19.2) 116 (20.3) 0.6376 
   Nitrates (at randomization) 43 (7.4) 38 (6.6) 0.6319 
Baseline laboratory variables    
   Sodium, mmol/L 141.0 (3.3) 140.7 (3.8) 0.2135 
   Hemoglobin, g/dL 12.9 (1.9) 12.6 (1.8) 0.0051* 
   White blood cell count, ×10
9
/L 8.6 (3.0) 7.8 (2.6) <0.0001* 
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   Lymphocyte, % 17.7 (8.0) 18.6 (7.6) 0.0533 
   Potassium, mmol/L 4.3 (0.6) 4.3 (0.6) 0.7394 
   Creatinine, umol/L 114.4 (33.8) 118.7 (32.3) 0.0321* 
   Uric acid, umol/L 463.3 (131.6) 488.5 (139.2) 0.0018* 
   BUN, mmol/L 9.3 (3.8) 10.2 (4.2) 0.0002* 
   eGFR
‡
, ml/min/1.73m
2
 53.2 (15.5) 52.2 (15.8) 0.2691 
   Alanine aminotransferase, U/L 31.5 (36.5) 28.1 (29.0) 0.0882 
   Aspartate aminotransferase, U/L 32.2 (32.8) 30.5 (27.9) 0.3725 
   Cystatin-C, mg/L
§
  
     - Median (1
st
 Quartile, 3
rd
 Quartile) 
1.4 (1.1, 1.7) 
(n=556) 
1.5 (1.2, 1.8) 
(n=546) 
<0.0001* 
   Troponin T, ng/mL
§
 
      - Median (1
st
 Quartile, 3
rd
 Quartile) 
0.03 (0.02, 0.06) 
(n=543) 
0.03 (0.02, 0.05) 
(n=532) 
0.2797 
   NT-proBNP, ng/L
§
 
      - Median (1
st
 Quartile, 3
rd
 Quartile) 
4997.0 (2826.5, 
9323.5) 
(n=556) 
4737.5 (2633.0, 
8657.0) 
(n=546) 
0.4148 
• In patients without AF at screening 
(N=647) 
5110.0 (2732.0, 
9904.5) 
(n=352) 
4124.0 (2379.0, 
8147.0) 
(n=295) 
0.0257*
║
 
• In patients with AF at screening 
(N=455) 
4665.5 (2848.0, 
8188.0) 
(n=204) 
5406.0 (3159.0, 
9009.0)  
(n=251) 
0.1373
║
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Continuous variables are expressed as mean (SD) or geometric mean (95%CI) and categorical variables as n (%), 
*Significant difference between “no/mild edema” vs. “moderate/severe edema”, p < 0.05 
†
p-values were based on two-sample t-test for continuous variables and chi-square test for categorical variables, 
‡
eGFR calculated by the simplified MDRD formula;
 
§
For the biomarkers, the summary statistics of median and IQR (inter-quartile range) and P-values based on non-
parametric Wilcoxon test are provided. 
║
P-value was based on analysis of variance including natural-log-
transformed NT-proBNP at baseline as the dependent variable and subgroup as the major factor.  
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; BUN, blood urea nitrogen; CI, confidence interval; 
eGFR, estimated glomerular filtration rate; ICD, implantable cardiac defibrillator; IV, intravenous; IQR, 
interquartile; MDRD, Modification of Diet for Renal Disease; NT-proBNP, N-terminal prohormone of brain 
natriuretic peptide 
 
Compared with placebo, serelaxin improved patient-reported dyspnea (VAS scores) in 
both subgroups, with a trend towards greater benefit in those with moderate/severe edema (Table 
3). No difference was observed in the assessment of dyspnea by the Likert scale at 6, 12 and 24 
hours in both subgroups (OR 0.99 and 1.10 in the moderate/severe and no/mild edema subgroups 
respectively, p for interaction = 0.6983).  
Patients assigned to serelaxin received lower cumulative doses of diuretics in both the 
subgroups, with the difference being statistically significant in the moderate/severe edema 
subgroup (serelaxin vs placebo mean difference: no/mild edema subgroup, -22 mg; p=0.1845 and 
moderate/severe edema subgroup, -78 mg; p = 0.0179), although the test for interaction was not 
significant (p-value for subgroup-by-treatment interaction = 0.1249). For patients with 
moderate/severe edema, reductions in body weight were similar for those assigned to serelaxin or 
placebo (LSM difference [95 % CI] = -0.005 [-0.6, 0.6] kg) while in those with no/mild edema, a 
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larger decrease in body weight was noted in patients assigned to placebo (LSM difference (95 % 
CI): 0.48 (0.07, 0.9) kg, p = 0.0225). 
In the no/mild edema subgroup, serelaxin-treated patients had a significantly shorter 
index LOS and time spent in ICU/CCU compared with the placebo group (mean LOS, serelaxin: 
8.3 days vs placebo: 10.1 days, p=0.0035; ICU/CCU stay, serelaxin: 2.7 days vs placebo: 3.8 
days, p=0.0282). However, no significant differences between the serelaxin and placebo arms 
were observed in the moderate/severe edema subgroup; further, no significant interaction 
between subgroup and treatment was observed (p=0.0667 for LOS and p=0.0835 for ICU/CCU 
stay).  
No significant differences were observed in the days alive and out of hospital endpoint or 
in the composite endpoint of CV death or HF/renal failure re-hospitalization through Day 60 
across subgroups and treatment arms. Overall, serelaxin reduced all-cause mortality through Day 
180 compared with placebo. The effect trended in a positive direction in the no/mild edema 
subgroup (HR [95 % CI] = 0.69 [0.4, 1.2], p = 0.2248) and was statistically significant in the 
moderate/severe edema subgroup (HR [95 % CI] = 0.58 [0.34, 0.97], p = 0.0361; Figure 1A). 
Similarly, treatment with serelaxin trended to reduce CV death through Day 180 compared with 
placebo in both subgroups (HR [95 % CI] =0.55 [0.3, 1.1], p = 0.0758 in the no/mild and 0.66 
[0.4, 1.16], p = 0.1451 in the moderate/severe subgroup; Figure 1B). In both subgroups, the 
incidence of WHF through Day 5 was lower for serelaxin-treated patients (no/mild edema: HR 
[95% CI]: 0.54 [0.3, 1.0], p = 0.0465; moderate/severe edema: 0.50 [0.3, 0.8], p = 0.0086; Figure 
1C). 
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Table 3: Treatment effect (serelaxin vs. placebo) on various outcomes in patients with “no/mild edema” (baseline edema score = 0/1) 
and “moderate/severe edema” (baseline edema score= 2/3) 
 
Outcome 
No/mild edema (Total N=583) Moderate/severe edema  (Total N=571) 
p-value† 
for 
interaction 
Treatment groups 
Between-treatment 
comparison: 
Serelaxin vs. Placebo 
Treatment groups 
Between-treatment 
comparison: 
Serelaxin vs. Placebo 
Placebo 
(N = 286) 
Serelaxin 
(N=297 ) 
Treatment effect 
(95% CI)†; p-value† 
Placebo 
(N =291 ) 
Serelaxin 
(N = 280) 
Treatment effect (95% 
CI)†; p-value† 
Dyspnea improvement, 
Likert Scale at 6, 12 and 
24 hours
§
,  n /N (%) 
80/286 (28.0%) 89/297 (30.0%) 
OR: 1.1 (0.77, 1.58); 
0.5958 
70/291 (24.0%) 67/280 (23.9%) 
OR: 0.99 (0.68, 1.46); 
0.9718 
0.6983 
Dyspnea improvement‡ to 
Day 5, Mean (SD) 
2612.0 (2973.7) 2792.8 (2699.0) 
180.8 (-280.8, 642.4); 
0.4421 
2017.0 (3169.2) 2755.5 (2467.3) 
738.5 (270.45, 1206.60) 
0.0020* 
0.0959 
Total dose of IV loop 
diuretics before Day 5, mg,  
Mean (SD) 
131.5 (195.7) 
n’ = 283 
109.6 (198.6) 
n’ = 292 
-21.8 (-54.2, 10.4) 
0.1845 
293.5 (452.6) 
n’ = 287 
215.6 (311.9) 
n’ = 278 
-77.9 (-142.3, -13.5) 
0.0179* 
0.1249 
Change in bodyweight to 
Day 5, kg, Mean (SD) 
-2.2 (2.7) 
n’ = 275 
-1.8 (2.3) 
n’ = 284 
0.48 (0.07, 0.9) 
0.0225* 
-3.7 (3.7) 
n’ = 284 
-3.7 (3.9) 
n’ = 270 
-0.005 (-0.6, 0.6) 
0.9882 
0.2063 
Length of initial hospital stay, days 
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Mean (SD) 10.1 (9.2) 8.3 (5.4) 
-1.8 (-3.0, -0.6) 
0.0035* 
10.8 (10.0) 11.0 (11.7) 
0.19 (-1.6, 2.0) 
0.8374 
0.0667 
Median (IQR)║ 8.0 ( 6.0, 11.0) 7.0 ( 5.0, 10.0) 
Median Diff ║, 
-1.0 (0.0, 1.0) 
0.0359* 
8.0 ( 6.0, 12.0) 8.0 ( 5.0, 11.0) 
Median Diff  ║,  
-1.0 (-1.0, 0.0) 
0.4250║ 
 
Length of stay ICU/CCU, days  
Mean (SD) 
3.8 (7.2) 
n’ = 286 
2.7 (3.6) 
n’ = 294 
-1.0 (-2.0, -0.1) 
0.0282* 
4.0 (6.8) 
n’ = 289 
4.4 (9.4) 
n’ = 278 
0.4 (-0.9, 1.7) 
0.5594 
0.0835 
Median (IQR)║ 2.0 ( 1.0, 4.0) 2.0 ( 0.0, 3.0) 
Median Diff ║ 
0.0 (0.0, 0.0) 
0.2904║ 
3.0 ( 0.0, 4.0) 2.0 ( 0.0, 4.0) 
Median Diff║, 0.0 (-1.0, 
0.0) 
0.0478* 
 
 WHF Through Day 5,  
n / N (%);KM% 
28/286 (9.8%); 
KM#=  9.9% 
16/297 (5.4%);         
KM#= 5.48% 
HR: 0.54 (0.3, 1.0); 
0.0465* (LR¶) 
41/291(14.1%); 
KM#=14.24% 
21/280 (7.5%);      
KM#= 7.55% 
HR: 0.5 (0.3, 0.8); 
0.0086* (LR¶) 
0.8565 
Days alive and out of hospital through Day 60 
   
0.99 (-0.7, 2.7); 
  
0.17 (-2.0, 2.3); 0.5563 
Mean (SD) 48.5 (11.2) 49.5 (9.6) 0.2530 46.8 (12.9) 47.0 (13.3) 0.8776  
Median (IQR)║ 52.0 ( 46.0, 55.0) 53.0 ( 47.0, 55.0) 
Median Diff ║ 
0.0 (-1.0, 0.0); 
0.4244║ 
52.0 ( 44.0, 54.0) 
 
52.0 ( 44.5, 55.0) 
Median Diff ║, 0.0 (-1.0, 
1.0); 
0.6881║ 
 
CV death or HF/RF 
hospitalization through 
33/286 (11.5%); 
KM#=11.6% 
30/297 (10.1%); 
KM#=10.2% 
HR: 0.88 (0.5, 1.4); 
0.6135 (LR¶) 
42/291 (14.4%); 
KM#= 14.6% 
45/280 
(16.1%); KM#= 
HR: 1.1 (0.7, 1.7); 
0.5593 (LR¶) 
0.4454 
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Day 60, n/N (%); KM %   16.2%  
All-cause death through 
Day 180: n/N (%); (KM)% 
26/286 (9.1%); 
KM#=  9.1% 
19/297 (6.4%);         
KM#= 6.5% 
HR: 0.69 (0.4, 1.2); 
0.2248 (LR¶) 
39/291 (13.4%); 
KM#= 13.6% 
22/280 (7.9%); 
KM#= 7.9% 
HR: 0.58 (0.3, 1.0);  
0.0361* (LR¶) 
0.6351 
CV death through Day 
180: n / N (%);KM % 
24/286 (8.4%); 
KM#=  8.4% 
14/297 (4.7%);         
KM#= 4.8% 
HR: 0.55 (0.3, 1.1); 
0.0758 (LR¶) 
31/291 (10.6%); 
KM#= 10.89% 
20/280 (7.1%): 
KM#= 7.2% 
HR: 0.66 (0.4, 1.2); 
0.1451(LR¶) 
0.7009 
Continuous variables are expressed as mean (SD), categorical variables as n/N (%), and time-to-event variables as n /N (%) + (KM %); n’ = number of subjects 
with non-missing data; *significant difference between “no/mild edema” vs. “moderate/severe edema”, p < 0.05. 
†
Treatment effect represents LSM difference for continuous variables, odds ratio (OR) for dichotomous variables, and hazard ratio (HR) for time-to-event 
variables, estimated from analysis of covariance model (ANCOVA), logistic regression, and Cox regression models, respectively. The 95% confidence intervals 
(CIs)  for the above estimated treatment effect along with p-value for between treatment comparison and subgroup-by-treatment interaction  are reported based 
on the aforementioned statistical models respectively.;  
‡
Dyspnea improvement to day 5 as assessed by VAS-AUC; 
§
Subjects with moderately or markedly better dyspnea as assessed by the Likert scale; 
║
For the endpoints, “length of initial hospital stay”, “days in IC/CCU”, and “days alive out of hospital through Day 60”, the summary statistics of median and 
IQR are also presented and the treatment effect is expressed as median difference and 95% CI based on Hodges-Lehmann estimation. P-value is based on non-
parametric Wilcoxon rank sum test. 
¶
LR: P-value of treatment effect for time-to-event endpoints is based on log-rank test; 
#
Kaplan-Meier cumulative event rates 
ANCOVA, analysis of covariance; AUC, area under the curve; CV, cardiovascular; HF, heart failure; ICU/CCU, intensive care unit/ coronary care unit; IQR, 
interquartile range; IV, intravenous; KM, Kaplan-Meier; LSM, least square mean; LSM, least square mean; OR, odds ratio; RF, renal failure.; SD, standard 
deviation; VAS, visual analogue scale; WHF, worsening heart failure 
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Figure 1.   Kaplan-Meier curves for (A) All-Cause Mortality through Day 180, (B) Cardiovascular Mortality through Day 180, 
and (C) Worsening Heart Failure through Day 5 
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HR, hazard ratio; PBO, placebo; RLX030, serelaxin 
*significant difference between “no/mild edema” vs. “moderate/severe edema”, p < 0.05. 
a
p values for treatment effects based on log-rank test
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DISCUSSION 
In this post-hoc analysis, patients with AHF from the RELAX-AHF trial were classified 
into two subgroups based on the absence or presence of baseline peripheral edema: no/mild and 
moderate/severe. The subgroup definition was an attempt to discern two different phenotypes of 
patients with AHF, with possible differences in the underlying pathophysiology (fluid retention 
vs. fluid redistribution) based on a very simple clinical variable.  
The analysis suggests that patients admitted with severe peripheral edema generally have 
worse outcomes but benefit from the administration of serelaxin as much in relative terms and 
perhaps, more in absolute terms, as do those admitted for breathlessness without an evidence of 
marked fluid retention. This suggests that serelaxin may not be acting solely as a vasodilator 
agent to reduce pulmonary capillary pressure and fluid redistribution. Improved renal function 
and reduction in diuretic requirements in patients treated with serelaxin point to a possible renal 
effect.  
Importantly, the two subgroups in this analysis were of similar size. Some of the 
differences in baseline characteristics were not unexpected: a higher proportion of female 
representation, slightly older population, as well as lower BMI were observed in the no/mild 
subgroup. In the moderate/severe subgroup, the proportion of patients with a history of hospital 
admission due to HF within the last year was higher and statistically significant. This was 
consistent with their baseline characteristics of a past history of HF and, consequently, an 
increased proportion of associated comorbidities such as diabetes, AF, and higher levels of renal 
markers suggesting more severe chronic kidney dysfunction. 
We observed higher NT-proBNP levels in patients without AF at screening in the no/mild 
edema group compared with moderate/severe edema group. These findings are somewhat counter 
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intuitive, as increased NT-proBNP levels would be expected both in patients with 
moderate/severe edema (as a consequence of the fluid overload), and in the subgroups with AF at 
screening as compared to those without, since AF is a known independent determinant of 
increased NT-proBNP. Although this observation could be a chance finding, it could also be due 
to differences in certain baseline characteristics such as renal function, paroxysmal AF post-
screening, age, gender differences, etc.  
Although we expected a higher LVEF in the no/mild group, the mean LVEF 
(approximately 38%) was similar in both subgroups. A chart review of echocardiograms as 
opposed to index visit echocardiograms may have contributed to this finding. The distribution of 
patients with AHF into those with mild or no peripheral edema vs. those with moderate to severe 
peripheral edema are consistent with previous registry data collected from more than 136000 
patients during six years in England and Wales(14). 
A similar useful and simplistic classification of patients with AHF into “puffers” and “bloaters” 
was described by Cleland et al (15,16). A classic “bloater” presents with increasing water 
retention, weight gain, peripheral edema and renal dysfunction. These patients have more severe 
pulmonary hypertension, right ventricular dysfunction and tricuspid regurgitation (17). Hepatic 
congestion impairs degradation of aldosterone which exacerbates sodium and fluid retention. 
These patients usually have a subacute presentation, and emergency treatment is often not 
required; yet they have a particularly poor prognosis. Some patients under the ‘bloaters’ group 
may not seek medical attention until pulmonary edema and severe breathlessness develop (15).  
In contrast, many “puffers” have little evidence of fluid retention. Their underlying 
problem appears to be redistribution of fluid from the circulation to the pulmonary alveoli due to 
capillary hypertension, which is often associated with an increase in systemic vascular resistance 
and an increased afterload. This may be driven by a vicious cycle of increased sympathetic 
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activation driven in part by the distress caused by dyspnea. Patients in this group may be better 
treated by vasodilators rather than diuretic agents (15). They typically present with a short history 
of severe breathlessness, requiring urgent treatment for symptom control. Many patients, 
however, fall between the extremes of these two presentations.  
While it can be argued that the presence of edema may be associated with multiple 
different clinical and pathophysiological conditions (e.g. nutrition and protein levels, endothelium 
integrity, venous competence, renal function etc.) and that the specificity of the evaluation is not 
very high, this “bedside assessment” is a simple clinical tool providing a first impression of the 
patient’s phenotype. However, this must be confirmed by further assessments with 
complementary analyses(15,18,19). 
While this classification is useful to understand the complexity of AHF presentation, it is 
not universally adopted. In the recently published European Society of Cardiology guidelines, an 
algorithm to characterize the hemodynamic profile of patients with AHF clearly shows that the 
presence of congestion (i.e. “wet”) is the most common presenting feature representing nearly 
95% of patients with AHF. The same algorithm also describes that the vast majority of patients 
are “wet” (congested) and “warm” (well perfused), typically presenting with normal or elevated 
BP. The algorithm further subcategorizes this population into vascular type-fluid redistribution 
(i.e. hypertension predominant) or cardiac type-fluid accumulation (i.e. congestion 
predominant)(18)  
In the present analysis, a statistically significant positive effect of serelaxin on dyspnea 
was observed in the moderate/severe edema subgroup while a positive trend was also seen in the 
no/mild edema subgroup. 
In accordance with our previous observations, no significant differences in the treatment 
effect were observed in the short to medium-term outcomes, as assessed by CV death through 
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Day 60 or the composite endpoint of CV death or HF/renal failure hospitalization at 60 days(1). 
A significant reduction in LOS was observed in the serelaxin-treated patients with no/mild 
edema.  
Overall, the mean dose of IV diuretic up to Day 5 was lower in serelaxin-treated patients 
in both subgroups. Although no significant treatment differences in diuretic use was observed in 
the no/mild subgroup (serelaxin vs placebo), this was particularly evident, and statistically 
significant in the moderate/severe edema group. The serelaxin-treated patients in this subgroup 
required almost 80 mg less furosemide than did the placebo-treated patients, despite both 
treatment arms showing similar decreases in body weight. This finding is in contrast with 
previous analyses on the diuretic response, which did not identify any potentiation effect of 
serelaxin (20). However, the same study suggested that a better diuretic response is expected in 
patients with more peripheral edema, an assumption that is supported in the present analysis (20).  
The reduction WHF through Day 5 is consistent with that seen in the main population (1). 
This is important for two reasons: (a) WHF has been recognized as a valid endpoint and has been 
demonstrated to have a good correlation with mortality(21), and (b) increased validity of the 
WHF endpoint for regulatory agencies. In the future, should these results be validated in 
prospective trials, this endpoint could be used as a surrogate for mortality. 
In accordance with the earlier observations, all cause and CV mortality were lower in 
patients assigned to serelaxin (1) with similar relative benefits in each subgroup. Indeed, the 
absolute benefit with serelaxin on all-cause mortality and WHF appeared somewhat greater in 
those with more severe edema.  
Contrary to what might be intuitively expected from a characteristic arterial vasodilator 
(i.e. a better response in those with fluid redistribution rather than fluid retention), this analysis 
suggests that benefits may be similar or greater in those with overt evidence of fluid retention. 
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Studies in pre-clinical models suggest a selective vasodilatory effect of serelaxin on certain 
venous vascular beds (such as renal and mesenteric beds)(22, 23). Further, pre-clinical and 
clinical evidence suggest that serelaxin reduces markers of renal and hepatic impairment possibly 
owing to its early decongestion effects and vasodilatory actions that improve perfusion and renal 
hemodynamics(24, 25). In accordance with these observations, we speculate that a putative target 
effect of serelaxin on these vascular beds could contribute to increased venous capacitance and 
decongestion of the kidney, liver and splanchnic tissue with potential long-term benefits. 
Alternatively, or in addition, specific effects on renal haemodynamics may improve diuretic 
responsiveness and unload the heart. This supports a targeted and specific mechanism of action 
that needs to be elucidated further.  
LIMITATIONS  
This was a post-hoc analysis and since the number of patients in each subgroup was 
small, the results should be interpreted with caution. Similarly, differences in the baseline 
characteristics of the population (e.g. different rates of AF across groups, and indicators of heart 
failure duration)  could have  contributed to the current observations.  Some patients may have 
been misclassified either because of inter-observer variability or because of the arbitrary 
definition applied to what is possibly a continuous distribution. A larger study might allow more 
complex classifications to be applied with more granular subgroups.  
 
CONCLUSIONS 
Patients with AHF and more severe peripheral edema have a worse prognosis but appear 
to receive similar relative (and perhaps greater) absolute benefit from administration of serelaxin 
for several outcomes, including early WHF, CV and all-cause mortality. Future trials in AHF 
(particularly RELAX-AHF-2) will help to determine the validity of these observations.   
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Figure titles and legends 
Figure 1. Effect of serelaxin (vs. placebo) treatment on mortality and WHF in patients with 
or without peripheral edema.   Kaplan-Meier curves for (A) All-Cause Mortality through Day 
180, (B) Cardiovascular Mortality through Day 180, and (C) Worsening Heart Failure through 
Day 5. 
HR, hazard ratio; PBO, placebo; RLX030, serelaxin 
*significant difference between “no/mild edema” vs. “moderate/severe edema”, p < 0.05. 
a
p values for treatment effects based on log-rank test 
